244: Pharma blockbusters, pandemic policy, & legal chicanery

Published: Feb. 2, 2023, 7:22 p.m.

STAT Washington correspondent Rachel Cohrs joins us to explain the looming end of Covid-19's status as a federal emergency and what that does and doesn't mean for public health. We also dig into the most interesting stories from a busy week of pharmaceutical earnings and discuss a legal setback for Johnson & Johnson.